{
    "paper_id": "PMC7168388",
    "metadata": {
        "title": "Laboratory diagnosis of human seasonal and pandemic influenza virus infection",
        "authors": [
            {
                "first": "Dominic",
                "middle": [
                    "E"
                ],
                "last": "Dwyer",
                "suffix": "",
                "email": "dominic_dwyer@wmi.usyd.edu.au",
                "affiliation": {}
            },
            {
                "first": "David",
                "middle": [
                    "W"
                ],
                "last": "Smith",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Michael",
                "middle": [
                    "G"
                ],
                "last": "Catton",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Ian",
                "middle": [
                    "G"
                ],
                "last": "Barr",
                "suffix": "",
                "email": null,
                "affiliation": {}
            }
        ]
    },
    "body_text": [
        {
            "text": "Recovery of virus from nasopharyngeal aspirates, nasal washes, and bronchoalveolar lavages is superior to that from nasopharyngeal and throat swabs and expectorated sputum,\n5\n\n\u2010\n\n7\n as the latter generally contain less columnar and more squamous epithelial cells. Single\u2010use swabs containing viral transport media are readily available commercially. Specimen requirements for antigen and nucleic acid testing are similar to those for virus isolation.",
            "cite_spans": [],
            "section": "Collection of respiratory tract specimens ::: Laboratory diagnosis",
            "ref_spans": []
        },
        {
            "text": "Early experience with human H5N1 infections suggests that virus is more readily detectable in lower respiratory tract samples. Upper respiratory tract samples are easier to collect, with the rate and load of detectable H5N1 RNA higher in samples collected from the pharynx (and the trachea) than the nose. Virus has been detected in serum, faeces and cerebrospinal fluid, reflecting the systemic nature of H5N1 infection, with viraemia associated with increased mortality.\n8\n\n",
            "cite_spans": [],
            "section": "Collection of respiratory tract specimens ::: Laboratory diagnosis",
            "ref_spans": []
        },
        {
            "text": "Serum specimens for serology should be collected during the acute phase within 7\u201310 days of symptom onset, and the convalescent phase 14\u201321 days after symptom onset, and tested in parallel.",
            "cite_spans": [],
            "section": "Collection of respiratory tract specimens ::: Laboratory diagnosis",
            "ref_spans": []
        },
        {
            "text": "The traditional method of influenza virus recovery from clinical specimens is by cell culture. However, the relatively slow turn\u2010around time (the time from receipt of specimens by a laboratory to a result being available to the clinician) of at least 4\u20135 days has led to the use of more rapid assays, such as nucleic acid testing or immunofluoresence, and fewer laboratories isolating virus. Nevertheless, virus isolation is usually more sensitive than the rapid culture and antigen detection assays, it recovers novel or highly divergent strains missed by other tests, it provides an isolate for subsequent characterisation and consideration as potential vaccine strains, and it allows the simultaneous recovery of other respiratory viruses if an appropriate range of cell lines is used.",
            "cite_spans": [],
            "section": "Virus isolation ::: Laboratory diagnosis",
            "ref_spans": []
        },
        {
            "text": "Influenza virus replication within cell culture, often using Madin Darby canine kidney cells, is detected by observing the cytopathic effect, generally manifested by 5 days.\n1\n Rapid culture techniques that detect influenza virus replication using labelled monoclonal antibodies within 1\u20133 days (before the development of cytopathic effect) have a sensitivity of 56%\u2013100% compared with conventional cell culture.\n9\n Virus is readily isolated (PC3 facilities are recommended) from the nose and throat of humans with H5N1 infection, as well as from blood and rectal swabs.\n8\n\n",
            "cite_spans": [],
            "section": "Virus isolation ::: Laboratory diagnosis",
            "ref_spans": []
        },
        {
            "text": "Virus isolation in the allantoic and amniotic cavities of 10\u201311\u2010day\u2010old embryonated chicken eggs is labour intensive and not commonly performed by diagnostic laboratories. However, it yields higher viral titres, and remains vital for vaccine production.",
            "cite_spans": [],
            "section": "Virus isolation ::: Laboratory diagnosis",
            "ref_spans": []
        },
        {
            "text": "Initial typing of influenza virus isolates is most rapidly and conveniently accomplished by immunofluoresence using commercially available type\u2010specific monoclonal antibodies, and should be performed as soon as possible after isolation. The reference virus subtyping method is the haemagglutination inhibition assay using specific antisera, a technique that characterises both antigenic drift and shift. More rapid subtyping techniques using monoclonal antibodies that differentiate between influenza A/H1N1, A/H3N2, and B virus subtypes have been developed for use on virus isolates, in rapid culture assays, and directly on clinical specimens.\n10\n\n,\n\n11\n Subtyping using reverse transcription polymerase chain reaction (RT\u2010PCR) with primers specific for various human and avian influenza strains can be performed on virus isolates or directly on clinical specimens.\n12\n\n\u2010\n\n14\n DNA microarrays have been used to detect type\u2010 and subtype\u2010specific amplification sequences.\n15\n\n",
            "cite_spans": [],
            "section": "Virus typing ::: Laboratory diagnosis",
            "ref_spans": []
        },
        {
            "text": "Sequencing of amplified haemagglutinin and neuraminidase genes is an important subtyping method, as it allows rapid identification of novel or highly divergent strains, the analysis of strain variation, and the determination of the origin of outbreaks.\n16\n Rapid sequencing of avian and human strains has been used to monitor the evolution of H5N1 viruses around the world, allowing an understanding of its spread, drug resistance and likely candidate vaccine strains.\n17\n\n",
            "cite_spans": [],
            "section": "Virus typing ::: Laboratory diagnosis",
            "ref_spans": []
        },
        {
            "text": "Immunofluoresence or enzyme immunoassay using commercial type\u2010specific monoclonal antibodies directed against conserved influenza antigens are the most common rapid assays performed directly on clinical specimens (Box 5), although they are starting to be replaced by nucleic acid testing. Indirect or direct immunofluoresence is 60%\u2013100% sensitive compared with cell culture.\n1\n\n,\n\n2\n As specimens are examined with a fluorescent microscope, an assessment of specimen quality can be made (and reported to the clinician): where few columnar epithelial cells are seen, the sensitivity of immunofluoresence is low and repeat specimen collection should be requested.",
            "cite_spans": [],
            "section": "Rapid antigen detection assays ::: Laboratory diagnosis",
            "ref_spans": [
                {
                    "start": 214,
                    "end": 219,
                    "mention": "Box 5",
                    "ref_id": "FIGREF1"
                }
            ]
        },
        {
            "text": "Monoclonal antibodies to other common respiratory pathogens, such as parainfluenza viruses types 1\u20133, adenovirus and respiratory syncytial virus, can be applied to the same specimen. H5N1\u2010specific immunofluoresence reagents are not yet routinely available.",
            "cite_spans": [],
            "section": "Rapid antigen detection assays ::: Laboratory diagnosis",
            "ref_spans": []
        },
        {
            "text": "The availability of the neuraminidase inhibitors has added impetus to the development of simple, rapid antigen detection assays, sometimes called point\u2010of\u2010care tests.\n1\n\n,\n\n2\n Typically, these tests produce a visual result on an immunochromatographic strip using influenza A or B nucleoprotein\u2010specific monoclonal antibodies within about 15 minutes of adding an extracted specimen (Box 6). Evaluations of these assays for H5N1 infection are limited, but for A/H3N2, A/H1N1 or B virus infections, they are 56%\u2013100% sensitive and 73%\u201399% specific compared with cell culture or immunofluoresence, and are 56%\u201374% sensitive compared with RT\u2010PCR.\n1\n\n,\n\n2\n\n,\n\n18\n As with other techniques, specimen quality is a major determinant of their performance. Ideally, when using rapid antigen tests, specimens for cell culture and immunofluoresence or nucleic acid testing should be submitted in parallel to improve sensitivity and to obtain viral isolates for further typing and vaccine analysis, although this strategy increases costs.",
            "cite_spans": [],
            "section": "Rapid antigen detection assays ::: Laboratory diagnosis",
            "ref_spans": [
                {
                    "start": 382,
                    "end": 387,
                    "mention": "Box 6",
                    "ref_id": "FIGREF2"
                }
            ]
        },
        {
            "text": "Rapid antigen tests are attractive where virology laboratory support is limited or remote from clinical services, or where laboratories may be overwhelmed (for example, at the height of seasonal outbreaks or during a pandemic). They may also have a role in doctors\u2019 surgeries, emergency departments, or \u201cfever clinics\u201d, to guide the early use of neuraminidase inhibitors, both for individuals or in outbreaks in closed environments, or during a pandemic.\n19\n They can also be used in community\u2010based surveillance programs.",
            "cite_spans": [],
            "section": "Rapid antigen detection assays ::: Laboratory diagnosis",
            "ref_spans": []
        },
        {
            "text": "Influenza virus RNA may be detected in clinical specimens by nucleic acid testing techniques such as RT\u2010PCR. A variety of \u201cin\u2010house\u201d nucleic acid testing assays using primers specific for a range of influenza virus genes, and various extraction, amplification and product detection methods have been described.\n12\n\n\u2010\n\n14\n\n,\n\n18\n\n,\n\n20\n Depending on primer selection, these assays may be type\u2010 or subtype\u2010specific. Primers that target nucleoprotein or matrix gene sequences are popular, as they detect all influenza subtypes.",
            "cite_spans": [],
            "section": "Nucleic acid testing ::: Laboratory diagnosis",
            "ref_spans": []
        },
        {
            "text": "Although some studies documented a similar sensitivity of nucleic acid testing to cell culture, others have reported 5%\u201315% more influenza virus detections using RT\u2010PCR.\n12\n\n,\n\n13\n\n,\n\n18\n Specimen quality, timing, and transportation conditions may be less critical for nucleic acid testing than for culture or antigen detection, as viable virus and intact infected cells need not be preserved. Influenza virus RNA is detectable for several days longer into the clinical course than is cultivable virus, potentially allowing a diagnosis to be made in late\u2010presenting patients. When specimen quality is limited, such as with community\u2010based surveillance programs involving postal submission of specimens, yields from RT\u2010PCR are significantly higher than from cell culture.\n12\n\n,\n\n13\n\n,\n\n21\n Nucleic acid testing using H5N1\u2010specific primers is the most sensitive assay for the diagnosis of human H5N1 infection.\n8\n\n",
            "cite_spans": [],
            "section": "Nucleic acid testing ::: Laboratory diagnosis",
            "ref_spans": []
        },
        {
            "text": "Although the turnaround time for nucleic acid testing is intermediate between cell culture and direct antigen detection, newer techniques can reduce this to 4\u20135 hours or less.\n20\n Multiplex RT\u2010PCR assays have been developed, and these can simultaneously detect influenza and other viral and bacterial respiratory pathogens directly in clinical specimens.\n1\n\n,\n\n20\n RT\u2010PCR can quantify the viral load in clinical specimens, as has been done in human H5N1\u2010infected patients to assess prognosis and measure antiviral efficacy.\n8\n\n,\n\n22\n Nucleic acid testing can subtype influenza viruses using subtype\u2010specific primers, and analyse strain variation through genetic sequencing, thus complementing the traditional role of antigenic characterisation of viral isolates.",
            "cite_spans": [],
            "section": "Nucleic acid testing ::: Laboratory diagnosis",
            "ref_spans": []
        },
        {
            "text": "Serology can be used where specimens for virus isolation or antigen detection are negative, inadequate, or unavailable. It also provides useful, if delayed, surveillance data. Serological diagnosis of influenza is retrospective, as it requires acute and convalescent serum samples. Furthermore, it generally does not provide information on the antigenic composition of circulating strains.",
            "cite_spans": [],
            "section": "Serology ::: Laboratory diagnosis",
            "ref_spans": []
        },
        {
            "text": "As influenza virus infection generally represents reinfection, most people have some pre\u2010existing immunity. Thus, the detection of influenza\u2010specific IgG or total antibodies on a single serum specimen is not diagnostic of recent infection. The definitive serological diagnosis of acute influenza requires the demonstration of increasing antibody titres on paired acute and convalescent serum samples. Unfortunately, acute specimens are frequently not collected. However, a single high antibody titre in the context of a compatible clinical illness during a period of circulating influenza activity provides presumptive evidence of recent infection.",
            "cite_spans": [],
            "section": "Serology ::: Laboratory diagnosis",
            "ref_spans": []
        },
        {
            "text": "A variety of influenza\u2010specific assays are available, including complement fixation, haemagglutination inhibition assay, single radial haemolysis, neutralisation, immunofluorescence and enzyme immunoassay. The traditional \u201cgold standard\u201d techniques for detecting influenza\u2010specific antibodies are neutralisation and the haemagglutination inhibition assay, as they can differentiate subtype\u2010specific (including H5N1) and strain\u2010specific serological responses. Antibody levels correlate accurately with protection from (or susceptibility to) influenza, and with vaccination responses. Complement fixation is more commonly used as it is easier to perform than the haemagglutination inhibition assay and neutralisation, but it does not distinguish between subtypes. Recent influenza infection is suggested by a fourfold rise in complement fixation titre or by a single high titre.\n1\n\n,\n\n23\n\n",
            "cite_spans": [],
            "section": "Serology ::: Laboratory diagnosis",
            "ref_spans": []
        },
        {
            "text": "Two classes of drugs are effective against influenza virus infection: the adamantane M2 channel inhibitors (amantadine and rimantadine), and the neuraminidase inhibitors (zanamivir and oseltamivir).\n24\n\n,\n\n25\n\n",
            "cite_spans": [],
            "section": "Antiviral susceptibility testing ::: Laboratory diagnosis",
            "ref_spans": []
        },
        {
            "text": "Amantadine resistance emerges within a few days of treatment onset in 25%\u201335% of patients, and is mediated by amino acid substitutions in the M2 transmembrane region. Adamantane resistance is increasing around the world.\n24\n\n,\n\n25\n Neuraminidase inhibitor resistance is most commonly associated with a variety of amino acid substitutions in the conserved residues of the neuraminidase enzyme active site. To date, however, viruses with these mutations have shown impaired replication in cell culture and animal models. Mutations in the haemagglutinin receptor\u2010binding site can occur, leading to reduced viral dependence on neuraminidase function.\n24\n Resistance to the neuraminidase inhibitors was rarely seen in immunocompetent humans during clinical trials, although more recent reports of children infected with influenza A in Japan, and some Vietnamese human H5N1 patients treated with neuraminidase inhibitors, showed that resistance may be more common than initially supposed.\n22\n\n,\n\n25\n Resistant mutations have been detected after treatment of immunocompromised individuals, a situation that requires further study.",
            "cite_spans": [],
            "section": "Antiviral susceptibility testing ::: Laboratory diagnosis",
            "ref_spans": []
        },
        {
            "text": "Drug resistance is tested using genotyping (sequence analyses of the neuraminidase gene) or phenotyping assays.\n24\n\n,\n\n25\n These assays are not routinely available, but after therapeutic failure or for surveillance purposes, isolates can be referred to the appropriate reference laboratory. Newer molecular methods that allow rapid resistance determination in a clinically relevant time frame (such as during a pandemic when neuraminidase inhibitors may be used extensively) are under development.",
            "cite_spans": [],
            "section": "Antiviral susceptibility testing ::: Laboratory diagnosis",
            "ref_spans": []
        },
        {
            "text": "Various laboratory techniques are available to detect influenza viruses, whether current human strains or a novel pandemic strain. During a pandemic, the level of laboratory service will vary between centres. Specialist virology laboratories will undertake a full range of influenza virus tests, including nucleic acid testing, rapid antigen detection, culture and typing of isolates for potential use in vaccines, and detection of antiviral drug resistance. Other laboratories may follow a more limited strategy depending on their location (eg, rural areas), their population (eg, public or private hospitals), and access to specialised laboratories.",
            "cite_spans": [],
            "section": "Discussion",
            "ref_spans": []
        },
        {
            "text": "A challenge for laboratories is ensuring that their assays are accurate for viruses (such as the current H5N1 strains) not yet circulating in Australia. Genetic variation may particularly affect nucleic acid testing, and the lack of clinical samples in Australia from H5N1\u2010infected individuals makes assessment of the various methods uncertain. Recent urgent funding from the National Health and Medical Research Council (NHMRC) has allowed the assessment and quality assurance of various H5N1\u2010specific assays.",
            "cite_spans": [],
            "section": "Discussion",
            "ref_spans": []
        },
        {
            "text": "Another major challenge will be determining diagnostic strat\u2010egies during the different pandemic phases. These will vary between laboratories depending on their virology expertise, capacity, patient populations, availability of various assays, and the stage of the pandemic. In the very early phases, where containment is paramount, highly sensitive tests such as pandemic strain\u2010specific nucleic acid testing are required. Testing will have to be rapid to identify the first arrivals and clusters of disease, and to allow early antiviral treatment, prophylaxis and infection control. Other causes of respiratory infection will need to be excluded. Early identification will require cooperation and communication between public health officers, treating clinicians, and public and private laboratories. If the pandemic becomes widespread in Australia, testing strategies may change. One could argue that clinical identification will then suffice, and that laboratory testing should be limited to patients requiring hospital admission or for particular outbreaks. Non\u2010pandemic strain\u2010specific influenza assays, such as immunofluorescence or immunochromatographic rapid antigen tests, may be useful in identifying influenza infection during these pandemic stages. Antiviral resistance testing is not yet routinely available in Australia, but will be important if antiviral drugs are used extensively during a pandemic.",
            "cite_spans": [],
            "section": "Discussion",
            "ref_spans": []
        },
        {
            "text": "This project was partially supported by NHMRC grant 382917. The image in Box 5 was provided by David Adams and Ken McPhie at the Centre for Infectious Diseases and Microbiology Laboratory Services, Institute of Clinical Pathology and Medical Research, Westmead Hospital.",
            "cite_spans": [],
            "section": "Acknowledgements",
            "ref_spans": [
                {
                    "start": 73,
                    "end": 78,
                    "mention": "Box 5",
                    "ref_id": "FIGREF1"
                }
            ]
        },
        {
            "text": "Our laboratories have undertaken clinical research projects funded by laboratory supply companies related to laboratory techniques discussed in this paper. Roche Products Pty Ltd paid travel expenses for Dominic Dwyer and David Smith to attend the Lancet pandemic influenza meeting, Singapore, April 2006.",
            "cite_spans": [],
            "section": "Competing Interests",
            "ref_spans": []
        }
    ],
    "ref_entries": {
        "TABREF0": {
            "text": "Box 2: Comparison of diagnostic techniques for human influenza virus infection\n",
            "type": "table"
        },
        "FIGREF0": {
            "text": "Box 1: National Notifiable Diseases Surveillance System records of laboratory detection of influenza viruses from 2004 to mid 2006",
            "type": "figure"
        },
        "FIGREF1": {
            "text": "Box 5: Rapid antigen immunofluorescence assay Assay performed on cells from a combined nose and throat swab, showing typical nuclear and cytoplasmic \u201capple\u2010green\u201d fluorescence after staining with monoclonal antibodies specific for influenza A.",
            "type": "figure"
        },
        "FIGREF2": {
            "text": "Box 6: Positive rapid antigen immunochromatographic strips (Quidel Quickvue*) The strips show positive reactions to influenza A and B. The central blue line is a control reaction to ensure a valid assay. * Quidel Corporation, San Diego, Calif, USA.",
            "type": "figure"
        }
    },
    "back_matter": [],
    "bib_entries": {
        "BIBREF0": {
            "title": "Laboratory diagnosis of influenza virus infection",
            "authors": [],
            "year": 2002,
            "venue": "Pathology",
            "volume": "34",
            "issn": "",
            "pages": "115-125",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF1": {
            "title": "Influenza",
            "authors": [],
            "year": 2003,
            "venue": "Lancet",
            "volume": "362",
            "issn": "",
            "pages": "1733-1744",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF2": {
            "title": "",
            "authors": [],
            "year": 1998,
            "venue": "Textbook of influenza",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF3": {
            "title": "Collaborating Centre for Reference and Research on Influenza, Melbourne",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF4": {
            "title": "The 1976 influenza epidemic in Melbourne",
            "authors": [],
            "year": 1978,
            "venue": "Med J Aust",
            "volume": "2",
            "issn": "",
            "pages": "45-49",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF5": {
            "title": "Isolation of viruses from nasopharyngeal secretions. Comparison of aspiration and swabbing as means of sample collection",
            "authors": [],
            "year": 1987,
            "venue": "J Infect Dis",
            "volume": "156",
            "issn": "",
            "pages": "415-416",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF6": {
            "title": "Prospective comparative study of culture specimens and methods in diagnosing influenza in adults",
            "authors": [],
            "year": 1998,
            "venue": "BMJ",
            "volume": "316",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF7": {
            "title": "Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia",
            "authors": [],
            "year": 2006,
            "venue": "Nat Med",
            "volume": "12",
            "issn": "",
            "pages": "1203-1207",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF8": {
            "title": "Rapid detection of influenza virus by shell vial assay with monoclonal antibodies",
            "authors": [],
            "year": 1986,
            "venue": "J Clin Microbiol",
            "volume": "24",
            "issn": "",
            "pages": "677-679",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF9": {
            "title": "Evaluation of monoclonal antibodies for subtyping of currently circulating human type A influenza viruses",
            "authors": [],
            "year": 1997,
            "venue": "J Clin Microbiol",
            "volume": "35",
            "issn": "",
            "pages": "1196-1198",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF10": {
            "title": "Type\u2010 and subtype\u2010specific detection of influenza viruses in clinical specimens by rapid culture assay",
            "authors": [],
            "year": 1995,
            "venue": "J Clin Microbiol",
            "volume": "33",
            "issn": "",
            "pages": "318-321",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF11": {
            "title": "Multiplex reverse transcription\u2010PCR for surveillance of influenza A and B viruses in England and Wales in 1995 and 1996",
            "authors": [],
            "year": 1997,
            "venue": "J Clin Microbiol",
            "volume": "35",
            "issn": "",
            "pages": "2076-2082",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF12": {
            "title": "Application of a fluorogenic PCR assay for typing and subtyping of influenza viruses in respiratory samples",
            "authors": [],
            "year": 2000,
            "venue": "J Clin Microbiol",
            "volume": "38",
            "issn": "",
            "pages": "1552-1558",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF13": {
            "title": "Multiplex PCR for typing and subtyping influenza and respiratory syncytial viruses",
            "authors": [],
            "year": 1998,
            "venue": "J Clin Microbiol",
            "volume": "36",
            "issn": "",
            "pages": "2990-2995",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF14": {
            "title": "Typing and subtyping using DNA microarrays and multiplex reverse transcriptase PCR",
            "authors": [],
            "year": 2001,
            "venue": "J Clin Microbiol",
            "volume": "39",
            "issn": "",
            "pages": "696-704",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF15": {
            "title": "Summer outbreak of respiratory disease in an Australian prison due to an influenza A/Fujian/411/2002(H3N2)\u2010like virus",
            "authors": [],
            "year": 2005,
            "venue": "Epidemiol Infect",
            "volume": "133",
            "issn": "",
            "pages": "107-112",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF16": {
            "title": "Evolution of H5N1 avian influenza viruses in Asia",
            "authors": [],
            "year": 2005,
            "venue": "Emerg Infect Dis",
            "volume": "11",
            "issn": "",
            "pages": "1515-1521",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF17": {
            "title": "Simultaneous detection and typing of influenza viruses A and B by a nested reverse transcription\u2010PCR: comparison to virus isolation and antigen detection by immunofluorescence and optical immunoassay (FLU OIA)",
            "authors": [],
            "year": 2001,
            "venue": "J Clin Microbiol",
            "volume": "39",
            "issn": "",
            "pages": "134-138",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF18": {
            "title": "Treat or test first? Decision analysis of empirical antiviral treatment of influenza virus infection versus treatment based on rapid results",
            "authors": [],
            "year": 2002,
            "venue": "J Clin Virol",
            "volume": "25",
            "issn": "",
            "pages": "15-21",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF19": {
            "title": "Simultaneous detection of influenza viruses A and B using real\u2010time quantitative PCR",
            "authors": [],
            "year": 2001,
            "venue": "J Clin Microbiol",
            "volume": "39",
            "issn": "",
            "pages": "196-200",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF20": {
            "title": "Rapid virological surveillance of community influenza infection in general practice",
            "authors": [],
            "year": 2000,
            "venue": "BMJ",
            "volume": "321",
            "issn": "",
            "pages": "736-737",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF21": {
            "title": "Oseltamivir resistance during treatment of influenza A (H5N1) infection",
            "authors": [],
            "year": 2005,
            "venue": "N Engl J Med",
            "volume": "353",
            "issn": "",
            "pages": "2667-2672",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF22": {
            "title": "Influenza virus serology \u2014 a comparative study",
            "authors": [],
            "year": 1999,
            "venue": "J Virol Methods",
            "volume": "78",
            "issn": "",
            "pages": "163-169",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF23": {
            "title": "Resistance of influenza viruses to neuraminidase inhibitors \u2014 a review",
            "authors": [],
            "year": 2000,
            "venue": "Antivir Res",
            "volume": "47",
            "issn": "",
            "pages": "1-17",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF24": {
            "title": "Antiviral resistance in influenza viruses \u2014 implications for management and pandemic response",
            "authors": [],
            "year": 2006,
            "venue": "N Engl J Med",
            "volume": "354",
            "issn": "",
            "pages": "785-788",
            "other_ids": {
                "DOI": []
            }
        }
    }
}